DOCSLIB.ORG

Supporting Information for Proteomics DOI 10.1002/Pmic.200401283

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supporting Information for Proteomics DOI 10.1002/Pmic.200401283 Supporting Information for Proteomics DOI 10.1002/pmic.200401283 Laura Bianchi, Cristina Canton, Luca Bini, Rosaria Orlandi, Sylvie Mnard, Alessandro Armini, Monica Cattaneo, Vitaliano Pallini, Luigi Rossi Bernardi and Ida Biunno Protein profile changes in the human breast cancer cell line MCF-7 in response to SEL1L gene induction ª 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.de Probe Set ID UniGene ID Representative Public ID Gene Title Gene Symbol E+E- M+M- E+M+ E-M- 38591_at 397073 D38501 postmeiotic segregation increased 2-like 5 PMS2L5 D NC D NC 37611_at 81791 AB008822 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) TNFRSF11B D NC D NC 40711_at 86405 AL049340 Splicing factor YT521-B YT521 D NC D NC 33540_at 378826 AL049233 Chromosome 10 open reading frame 18 C10orf18 D NC D NC 1298_at 510244 X86816 Estrogen receptor cDNA, 5' splice variant --- D NC D NC 38266_at 188553 W25798 retinoblastoma binding protein 6 RBBP6 D NC D NC 31665_s_at --- W27675 --- --- D NC D NC 40713_at 86998 AB020634 nuclear factor of activated T-cells 5, tonicity-responsive NFAT5 D NC D NC 33658_at 421238 S54641 zinc finger protein 124 (HZF-16) ZNF124 D NC D NC 1465_s_at 300592 S75881 V-myb myeloblastosis viral oncogene homolog (avian)-like 1 MYBL1 D NC D NC 36448_at --- X95677 --- --- D NC D NC 34777_at 441047 D14874 adrenomedullin ADM D NC D NC 32389_at 536594 W25892 Transcribed locus, weakly similar to XP_216369.2 similar to ORF2 consensus sequence encoding endonuclease and reverse--- transcriptase minus DRNaseHNC [RattusD norvegicus]NC 39591_s_at 351808 Z36531 fibrinogen-like 2 FGL2 D NC D NC 40215_at 432605 D50840 UDP-glucose ceramide glucosyltransferase UGCG D NC D NC 40949_at 369068 AF035812 dynein, cytoplasmic, light intermediate polypeptide 2 DNCLI2 D NC D NC 39101_at 931 S73840 myosin, heavy polypeptide 2, skeletal muscle, adult MYH2 D NC D NC 40942_g_at --- W27026 --- --- D NC D NC 40604_at 173135 Y13493 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 DYRK2 D NC D NC 208_at 150917 M94151 catenin (cadherin-associated protein), alpha 2 CTNNA2 D NC D NC 35494_at 388400 M55536 Pantothenate kinase 3 PANK3 D NC D NC 32503_at 67619 AB007957 sorting nexin family member 27 SNX27 D NC D NC 1900_at 408528 L41870 retinoblastoma 1 (including osteosarcoma) RB1 D NC D NC 35440_g_at 440835 D26121 splicing factor 1 SF1 D NC D NC 32636_f_at 212761 AB007881 PI-3-kinase-related kinase SMG-1 SMG1 D NC D NC 1935_at 136965 AF007111 Mdm4, transformed 3T3 cell double minute 4, p53 binding protein (mouse) MDM4 D NC D NC 807_at 445862 U57092 RAB30, member RAS oncogene family RAB30 D NC D NC 305_g_at --- HG961-HT961 --- --- D NC D NC 32683_at 11355 U18271 thymopoietin TMPO D NC D NC AFFX-HUMISGF3A/M97935_5_at 21486 M97935 signal transducer and activator of transcription 1, 91kDa STAT1 D NC D NC 38557_at 135892 U75330 neural cell adhesion molecule 2 NCAM2 D NC D NC 33353_at 259768 W26466 adenylate cyclase 1 (brain) ADCY1 D NC D NC 33864_at 145894 X86098 zinc finger, MYND domain containing 11 ZMYND11 D NC D NC 248_at 30212 L40388 thyroid receptor interacting protein 15 TRIP15 D NC D NC 36435_at 130036 AF070670 protein phosphatase 1A (formerly 2C), magnesium-dependent, alpha isoform PPM1A D NC D NC 37622_r_at 142498 AF063020 PC4 and SFRS1 interacting protein 1 PSIP1 D NC D NC 748_s_at 118630 D63940 MAX interactor 1 MXI1 D NC D NC 31324_at 444957 U82303 ATPase, aminophospholipid transporter-like, Class I, type 8A, member 2 ATP8A2 MD NC MD NC 33599_at 445862 U57092 RAB30, member RAS oncogene family RAB30 D NC D NC 32911_s_at --- AA931204 --- --- D NC D NC 40343_at --- AJ005814 --- --- D NC D NC 40683_at 411881 L76687 growth factor receptor-bound protein 14 GRB14 D NC D NC 41301_at --- W28608 --- --- D NC D NC 1882_g_at --- HG4058-HT4328 --- --- D NC D NC 1078_at 212892 M31661 prolactin receptor PRLR D NC D NC 35600_at 374634 AB023967 ROD1 regulator of differentiation 1 (S. pombe) ROD1 D NC D NC 33538_at --- H96671 --- --- D NC D NC 34717_s_at 3530 AF047448 FUS interacting protein (serine-arginine rich) 1 FUSIP1 D NC D NC 32815_at --- AI687419 --- --- D NC D NC 37681_i_at --- AB018266 --- --- D NC D NC 33148_at 173518 AI459274 zinc finger RNA binding protein ZFR D NC D NC 2033_s_at 249441 U10564 WEE1 homolog (S. pombe) WEE1 D NC D NC 1037_at 2355 U19180 B melanoma antigen BAGE D NC D NC 32871_at 16364 AL049263 Paraspeckle component 1 PSPC1 D NC D NC 36216_at 267812 AF065485 sorting nexin 4 SNX4 D NC D NC 41298_at 367638 AF027156 mannosidase, alpha, class 1A, member 2 MAN1A2 D NC D NC 262_at 159118 M21154 adenosylmethionine decarboxylase 1 AMD1 D NC D NC 32638_s_at 212761 AI610467 PI-3-kinase-related kinase SMG-1 SMG1 D NC D NC 1818_at --- HG1879-HT1919 --- --- D NC D NC 1793_at 404501 M80629 cell division cycle 2-like 5 (cholinesterase-related cell division controller) CDC2L5 D NC D NC 653_at 443227 L07540 replication factor C (activator 1) 5, 36.5kDa RFC5 D NC D NC 34584_at 381285 L75847 zinc finger protein 45 (a Kruppel-associated box (KRAB) domain polypeptide) ZNF45 D NC D NC 36414_s_at 460584 AF032119 calcium/calmodulin-dependent serine protein kinase (MAGUK family) CASK D NC D NC 38170_at 154336 AF070595 Clone 24583 mRNA sequence --- D NC D NC 37531_at 115740 D86965 TBC1 domain family, member 5 TBC1D5 D NC D NC 40100_at 337774 U72206 rho/rac guanine nucleotide exchange factor (GEF) 2 ARHGEF2 D NC D NC 40553_at 519639 AI742087 Integral membrane glycoprotein-like LOC166994 D NC D NC 41815_at 129541 AL080133 spectrin repeat containing, nuclear envelope 2 SYNE2 D NC D NC 33468_at 412597 Z26317 desmoglein 2 DSG2 D NC D NC 36235_at --- W26334 --- --- D NC D NC 37173_at 75573 Z15005 centromere protein E, 312kDa CENPE D NC D NC 37286_at 7912 AB002341 neuronal cell adhesion molecule NRCAM D NC D NC 36101_s_at 73793 M63978 vascular endothelial growth factor VEGF D NC D NC 39562_at 444818 AF094481 CGG triplet repeat binding protein 1 CGGBP1 D NC D NC AFFX-HUMTFRR/M11507_5_at 185726 M11507 transferrin receptor (p90, CD71) TFRC D NC D NC 31670_s_at 237825 U81554 signal recognition particle 72kDa SRP72 D NC D NC 34112_r_at 154163 AL050065 HMT1 hnRNP methyltransferase-like 1 (S. cerevisiae) HRMT1L1 D NC D NC 35572_f_at --- AF038951 zinc finger protein 253 ZNF253 D NC D NC 39269_at 115474 L07541 replication factor C (activator 1) 3, 38kDa RFC3 D NC D NC 40822_at 172674 L41067 nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3 NFATC3 D NC D NC 34878_at 212957 AB019987 SMC4 structural maintenance of chromosomes 4-like 1 (yeast) SMC4L1 D NC D NC 36210_g_at 75243 S78771 bromodomain containing 2 BRD2 D NC D NC 1773_at 276 L00635 farnesyltransferase, CAAX box, beta FNTB D NC D NC 1479_g_at 211576 L10717 IL2-inducible T-cell kinase ITK D NC D NC 1164_at --- HG3344-HT3521 --- --- D NC D NC 960_g_at --- HG2463-HT2559 --- --- D NC D NC 112_g_at 1179 X07024 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 250kDa TAF1 D NC D NC 34963_at --- AA557228 --- --- D NC D NC 37507_i_at 298735 AA675900 formin binding protein 3 FNBP3 D NC D NC 37837_at 131915 AB020670 KIAA0863 protein KIAA0863 D NC D NC 39962_at 18586 U59305 CDC42 binding protein kinase alpha (DMPK-like) CDC42BPA D NC D NC 40660_at 279522 D85242 nuclear receptor subfamily 4, group A, member 3 NR4A3 D NC D NC 32131_at 409210 AB014575 zinc finger DAZ interacting protein 3 DZIP3 D NC D NC 40088_at 155017 X84373 nuclear receptor interacting protein 1 NRIP1 D NC D NC 33457_at 476396 AB029028 retinoblastoma-associated protein 140 RAP140 D NC D NC 35833_at 7089 AL080184 insulin induced gene 2 INSIG2 D NC D NC 40937_at 285848 AA160056 zinc finger protein 291 ZNF291 D NC D NC 1937_at --- HG4036-HT4306 --- --- D NC D NC 1784_s_at 19110 S66427 AT rich interactive domain 4A (RBP1-like) ARID4A D NC D NC 1654_at 162967 M95712 v-raf murine sarcoma viral oncogene homolog B1 BRAF D NC D NC 944_s_at 503095 D49354 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 PPFIA1 D NC D NC 263_g_at 159118 M21154 adenosylmethionine decarboxylase 1 AMD1 D NC D NC 34544_at 145498 X78925 zinc finger protein 267 ZNF267 D NC D NC 34967_at 498879 AF001549 similar to RNA polymerase I transcription factor RRN3 LOC94431 D NC D NC 35488_at 179312 U44754 small nuclear RNA activating complex, polypeptide 1, 43kDa SNAPC1 D NC D NC 39231_at 311553 AF006513 chromodomain helicase DNA binding protein 1 CHD1 D NC D NC 37183_at 420036 M81883 glutamate decarboxylase 1 (brain, 67kDa) GAD1 D NC D NC 39788_at 277132 U81005 plakophilin 4 PKP4 D NC D NC 40487_at --- W26634 --- --- D NC D NC 39810_at 369785 AC005253 hypothetical protein MGC2749 MGC2749 D NC D NC 40166_at --- AA923149 --- --- D NC D NC 40252_g_at 511765 U00943 HIV-1 rev binding protein 2 HRB2 D NC D NC 32571_at 77502 X68836 methionine adenosyltransferase II, alpha MAT2A D NC D NC 1753_s_at 440960 AD000092 RAD23 homolog A (S. cerevisiae) RAD23A D NC D NC 1565_s_at 411366 M96995 growth factor receptor-bound protein 2 GRB2 D NC D NC 1013_at 167700 U59913 SMAD, mothers against DPP homolog 5 (Drosophila) SMAD5 D NC D NC 33079_at 518435 AJ002078 syntaxin 6 STX6 D NC D NC 33669_at --- M69296 --- --- D NC D NC 34175_r_at 368302 AL049242 Similar to KIAA0393 protein MGC57820 D NC D NC 35603_at --- AL050030 --- --- D NC D NC 34472_at 276005 AB012911 frizzled homolog 6 (Drosophila) FZD6 D NC D NC 38908_s_at 232021 AL096744 REV3-like, catalytic subunit of DNA polymerase zeta (yeast) REV3L D NC D NC 39267_at 237323 AF102265 phosphoglucomutase 3 PGM3 D NC D NC 34234_f_at 369815 AI688640 natural killer-tumor recognition sequence NKTR D NC D NC 35812_at 412527 AJ133769 transportin 3 TNPO3 D NC D NC 40962_s_at 396404 D26155 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 SMARCA2 D NC D NC 1943_at 85137 X51688 cyclin A2 CCNA2 D NC D NC 861_g_at 440394 U03911 mutS homolog 2, colon cancer, nonpolyposis type 1 (E.
Load more

Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Figure S1. HAEC ROS Production and ML090 NOX5-Inhibition
    Figure S1. HAEC ROS production and ML090 NOX5-inhibition. (a) Extracellular H2O2 production in HAEC treated with ML090 at different concentrations and 24 h after being infected with GFP and NOX5-β adenoviruses (MOI 100). **p< 0.01, and ****p< 0.0001 vs control NOX5-β-infected cells (ML090, 0 nM). Results expressed as mean ± SEM. Fold increase vs GFP-infected cells with 0 nM of ML090. n= 6. (b) NOX5-β overexpression and DHE oxidation in HAEC. Representative images from three experiments are shown. Intracellular superoxide anion production of HAEC 24 h after infection with GFP and NOX5-β adenoviruses at different MOIs treated or not with ML090 (10 nM). MOI: Multiplicity of infection. Figure S2. Ontology analysis of HAEC infected with NOX5-β. Ontology analysis shows that the response to unfolded protein is the most relevant. Figure S3. UPR mRNA expression in heart of infarcted transgenic mice. n= 12-13. Results expressed as mean ± SEM. Table S1: Altered gene expression due to NOX5-β expression at 12 h (bold, highlighted in yellow). N12hvsG12h N18hvsG18h N24hvsG24h GeneName GeneDescription TranscriptID logFC p-value logFC p-value logFC p-value family with sequence similarity NM_052966 1.45 1.20E-17 2.44 3.27E-19 2.96 6.24E-21 FAM129A 129. member A DnaJ (Hsp40) homolog. NM_001130182 2.19 9.83E-20 2.94 2.90E-19 3.01 1.68E-19 DNAJA4 subfamily A. member 4 phorbol-12-myristate-13-acetate- NM_021127 0.93 1.84E-12 2.41 1.32E-17 2.69 1.43E-18 PMAIP1 induced protein 1 E2F7 E2F transcription factor 7 NM_203394 0.71 8.35E-11 2.20 2.21E-17 2.48 1.84E-18 DnaJ (Hsp40) homolog.
    [Show full text]
  • Strand Breaks for P53 Exon 6 and 8 Among Different Time Course of Folate Depletion Or Repletion in the Rectosigmoid Mucosa
    SUPPLEMENTAL FIGURE COLON p53 EXONIC STRAND BREAKS DURING FOLATE DEPLETION-REPLETION INTERVENTION Supplemental Figure Legend Strand breaks for p53 exon 6 and 8 among different time course of folate depletion or repletion in the rectosigmoid mucosa. The input of DNA was controlled by GAPDH. The data is shown as ΔCt after normalized to GAPDH. The higher ΔCt the more strand breaks. The P value is shown in the figure. SUPPLEMENT S1 Genes that were significantly UPREGULATED after folate intervention (by unadjusted paired t-test), list is sorted by P value Gene Symbol Nucleotide P VALUE Description OLFM4 NM_006418 0.0000 Homo sapiens differentially expressed in hematopoietic lineages (GW112) mRNA. FMR1NB NM_152578 0.0000 Homo sapiens hypothetical protein FLJ25736 (FLJ25736) mRNA. IFI6 NM_002038 0.0001 Homo sapiens interferon alpha-inducible protein (clone IFI-6-16) (G1P3) transcript variant 1 mRNA. Homo sapiens UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 15 GALNTL5 NM_145292 0.0001 (GALNT15) mRNA. STIM2 NM_020860 0.0001 Homo sapiens stromal interaction molecule 2 (STIM2) mRNA. ZNF645 NM_152577 0.0002 Homo sapiens hypothetical protein FLJ25735 (FLJ25735) mRNA. ATP12A NM_001676 0.0002 Homo sapiens ATPase H+/K+ transporting nongastric alpha polypeptide (ATP12A) mRNA. U1SNRNPBP NM_007020 0.0003 Homo sapiens U1-snRNP binding protein homolog (U1SNRNPBP) transcript variant 1 mRNA. RNF125 NM_017831 0.0004 Homo sapiens ring finger protein 125 (RNF125) mRNA. FMNL1 NM_005892 0.0004 Homo sapiens formin-like (FMNL) mRNA. ISG15 NM_005101 0.0005 Homo sapiens interferon alpha-inducible protein (clone IFI-15K) (G1P2) mRNA. SLC6A14 NM_007231 0.0005 Homo sapiens solute carrier family 6 (neurotransmitter transporter) member 14 (SLC6A14) mRNA.
    [Show full text]
  • Epigenetic Mechanisms Are Involved in the Oncogenic Properties of ZNF518B in Colorectal Cancer
    Epigenetic mechanisms are involved in the oncogenic properties of ZNF518B in colorectal cancer Francisco Gimeno-Valiente, Ángela L. Riffo-Campos, Luis Torres, Noelia Tarazona, Valentina Gambardella, Andrés Cervantes, Gerardo López-Rodas, Luis Franco and Josefa Castillo SUPPLEMENTARY METHODS 1. Selection of genomic sequences for ChIP analysis To select the sequences for ChIP analysis in the five putative target genes, namely, PADI3, ZDHHC2, RGS4, EFNA5 and KAT2B, the genomic region corresponding to the gene was downloaded from Ensembl. Then, zoom was applied to see in detail the promoter, enhancers and regulatory sequences. The details for HCT116 cells were then recovered and the target sequences for factor binding examined. Obviously, there are not data for ZNF518B, but special attention was paid to the target sequences of other zinc-finger containing factors. Finally, the regions that may putatively bind ZNF518B were selected and primers defining amplicons spanning such sequences were searched out. Supplementary Figure S3 gives the location of the amplicons used in each gene. 2. Obtaining the raw data and generating the BAM files for in silico analysis of the effects of EHMT2 and EZH2 silencing The data of siEZH2 (SRR6384524), siG9a (SRR6384526) and siNon-target (SRR6384521) in HCT116 cell line, were downloaded from SRA (Bioproject PRJNA422822, https://www.ncbi. nlm.nih.gov/bioproject/), using SRA-tolkit (https://ncbi.github.io/sra-tools/). All data correspond to RNAseq single end. doBasics = TRUE doAll = FALSE $ fastq-dump -I --split-files SRR6384524 Data quality was checked using the software fastqc (https://www.bioinformatics.babraham. ac.uk /projects/fastqc/). The first low quality removing nucleotides were removed using FASTX- Toolkit (http://hannonlab.cshl.edu/fastxtoolkit/).
    [Show full text]
  • Supp Data.Pdf
    Supplementary Methods Verhaak sub-classification The Verhaak called tumor subtype was assigned as determined in the Verhaak et al. manuscript, for those TCGA tumors that were included at the time. TCGA data for expression (Affymetrix platform, level 1) and methylation (Infinium platform level 3) were downloaded from the TCGA portal on 09/29/2011. Affymetrix data were processed using R and Biocondutor with a RMA algorithm using quantile normalization and custom CDF. Level 3 methylation data has already been processed and converted to a beta-value. The genes that make up the signature for each of the 4 Verhaak groups (i.e. Proneural, Neural, Mesenchymal, and Classical) were downloaded. For each tumor, the averaged expression of the 4 genes signatures was calculated generating 4 ‘metagene’ scores, one for each subtype, (Colman et al.2010) for every tumor. Then each subtype metagene score was z-score corrected to allow comparison among the 4 metagenes. Finally, for each tumor the subtype with the highest metagene z-score among the four was used to assign subtype. Thus by this method, a tumor is assigned to the group to which it has the strongest expression signature. The shortcoming is that if a tumor has a ‘dual personality’ – for instance has strong expression of both classical and mesenchymal signature genes, there is some arbitrariness to the tumor’s assignment. Western Blot Analysis and cell fractionation Western blot analysis was performed using standard protocols. To determine protein expression we used the following antibodies: TAZ (Sigma and BD Biosciences), YAP (Santa Cruz Biotechnology), CD44 (Cell Signaling), FN1 (BD Biosciences), TEAD1, TEAD2, TEAD3, TEAD4 (Santa Cruz Biotechnology), MST1, p-MST1, MOB1, LATS1, LATS2, 14-3-3-, 1 ACTG2, (Cell Signaling), p-LATS1/2 (Abcam), Flag (Sigma Aldrich), Actin (Calbiochem), CAV2 (BD Biosciences), CTGF (Santa Cruz), RUNX2 (Sigma Aldrich), Cylin A, Cyclin E, Cyclin B1, p-cdk1, p-cdk4 (Cell Signaling Technologies).
    [Show full text]
  • Single-Cell RNA Landscape of Intratumoral Heterogeneity and Immunosuppressive Microenvironment in Advanced Osteosarcoma
    ARTICLE https://doi.org/10.1038/s41467-020-20059-6 OPEN Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma Yan Zhou1,11, Dong Yang2,11, Qingcheng Yang2,11, Xiaobin Lv 3,11, Wentao Huang4,11, Zhenhua Zhou5, Yaling Wang 1, Zhichang Zhang2, Ting Yuan2, Xiaomin Ding1, Lina Tang 1, Jianjun Zhang1, Junyi Yin1, Yujing Huang1, Wenxi Yu1, Yonggang Wang1, Chenliang Zhou1, Yang Su1, Aina He1, Yuanjue Sun1, Zan Shen1, ✉ ✉ ✉ ✉ Binzhi Qian 6, Wei Meng7,8, Jia Fei9, Yang Yao1 , Xinghua Pan 7,8 , Peizhan Chen 10 & Haiyan Hu1 1234567890():,; Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA- sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic osteosarcoma lesions, 11 major cell clusters are identified based on unbiased clustering of gene expression profiles and canonical markers. The transcriptomic properties, regulators and dynamics of osteosarcoma malignant cells together with their tumor microenvironment particularly stromal and immune cells are characterized. The transdifferentiation of malignant osteoblastic cells from malignant chondroblastic cells is revealed by analyses of inferred copy-number variation and trajectory. A proinflammatory FABP4+ macrophages infiltration is noticed in lung metastatic osteosarcoma lesions. Lower osteoclasts infiltration is observed in chondroblastic, recurrent and lung metastatic osteosarcoma lesions compared to primary osteoblastic osteosarcoma lesions. Importantly, TIGIT blockade enhances the cytotoxicity effects of the primary CD3+ T cells with high proportion of TIGIT+ cells against osteo- sarcoma. These results present a single-cell atlas, explore intratumor heterogeneity, and provide potential therapeutic targets for osteosarcoma. 1 Oncology Department of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China.
    [Show full text]
  • Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors
    University of Cincinnati Date: 12/20/2010 I, Arturo R Maldonado , hereby submit this original work as part of the requirements for the degree of Doctor of Philosophy in Developmental Biology. It is entitled: Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors Student's name: Arturo R Maldonado This work and its defense approved by: Committee chair: Jeffrey Whitsett Committee member: Timothy Crombleholme, MD Committee member: Dan Wiginton, PhD Committee member: Rhonda Cardin, PhD Committee member: Tim Cripe 1297 Last Printed:1/11/2011 Document Of Defense Form Molecular Targeting and Enhancing Anticancer Efficacy of Oncolytic HSV-1 to Midkine Expressing Tumors A dissertation submitted to the Graduate School of the University of Cincinnati College of Medicine in partial fulfillment of the requirements for the degree of DOCTORATE OF PHILOSOPHY (PH.D.) in the Division of Molecular & Developmental Biology 2010 By Arturo Rafael Maldonado B.A., University of Miami, Coral Gables, Florida June 1993 M.D., New Jersey Medical School, Newark, New Jersey June 1999 Committee Chair: Jeffrey A. Whitsett, M.D. Advisor: Timothy M. Crombleholme, M.D. Timothy P. Cripe, M.D. Ph.D. Dan Wiginton, Ph.D. Rhonda D. Cardin, Ph.D. ABSTRACT Since 1999, cancer has surpassed heart disease as the number one cause of death in the US for people under the age of 85. Malignant Peripheral Nerve Sheath Tumor (MPNST), a common malignancy in patients with Neurofibromatosis, and colorectal cancer are midkine- producing tumors with high mortality rates. In vitro and preclinical xenograft models of MPNST were utilized in this dissertation to study the role of midkine (MDK), a tumor-specific gene over- expressed in these tumors and to test the efficacy of a MDK-transcriptionally targeted oncolytic HSV-1 (oHSV).
    [Show full text]
  • SUPPLEMENTARY MATERIALS and METHODS PBMC Transcriptomics
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut SUPPLEMENTARY MATERIALS AND METHODS PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF Contents l Supplementary methods l Supplementary Figure 1 l Supplementary Figure 2 l Supplementary Figure 3 l Supplementary Figure 4 l Supplementary Figure 5 l Supplementary Table 1 l Supplementary Table 2 l Supplementary Table 3 l Supplementary Table 4 l Supplementary Tables 5-14 l Supplementary Table 15 l Supplementary Table 16 l Supplementary Table 17 Li J, et al. Gut 2021;0:1–13. doi: 10.1136/gutjnl-2020-323395 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut SUPPLEMENTARY METHODS Test for HBV DNA The levels of HBV DNA were detected using real-time PCR with a COBAS® AmpliPrep/COBAS® TaqMan 48 System (Roche, Basel, Switzerland) and HBV Test v2.0. Criteria for diagnosing cirrhosis Pathology The gold standard for the diagnosis of cirrhosis is a liver biopsy obtained through a percutaneous or transjugular approach.1 Ultrasonography was performed 2-4 hours before biopsy. Liver biopsy specimens were obtained by experienced physicians. Percutaneous transthoracic puncture of the liver was performed according to the standard criteria. After biopsy, patients were monitored in the hospital with periodic analyses of haematocrit and other vital signs for 24 hours. Cirrhosis was diagnosed according to the globally agreed upon criteria.2 Cirrhosis is defined based on its pathological features under a microscope: (a) the presence of parenchymal nodules, (b) differences in liver cell size and appearance, (c) fragmentation of the biopsy specimen, (d) fibrous septa, and (d) an altered architecture and vascular relationships.
    [Show full text]
  • The Colors in This Table Match the Colored Gene Groups in Figure 2
    Supplementary Table S3 a: The colors in this table match the colored gene groups in Figure 2. Specifically acetylated genes in cHL (n=211) and B-cell lines (B1AC in Figure 2: n=327) determined by the cHL versus B-cell line comparison. Furthermore the 141 genes which were found in the intersection of the two B-cell groups (which are therefore jointly hypoacetylated in cHL and PCM cell lines) are marked in blue. Name Entrez Gene Ref Seq p-value (Acetylation) Ratio SEMA4C 54910 NM_017789.4 3,66E-006 -8,376854452 IL6 3569 NM_000600.2 1,77E-005 -8,314958127 ONECUT2 9480 NM_004852.2 4,00E-006 -8,282444977 IFIH1 64135 NM_022168.2 8,05E-006 -8,148979811 MARCKS 4082 NM_002356.5 3,00E-006 -8,132604423 BATF3 55509 NM_018664.1 5,26E-006 -8,091403371 CISH 1154 NM_145071.1 5,75E-005 -7,96206129 MAPKAPK3 7867 NM_004635.3 3,68E-005 -7,940750902 MEIS1 4211 NM_002398.2 6,76E-006 -7,771709205 FUT4 2526 NM_002033.2 6,72E-006 -7,720048774 CCR7 1236 NM_001838.2 3,01E-006 -7,716010702 ATF3 467 NM_001040619.1 3,97E-006 -7,640583425 IRF4 3662 NM_002460.1 4,87E-006 -7,625499983 BEND6 221336 NM_152731.2 1,33E-005 -7,576292802 EHBP1 23301 NM_015252.2 3,88E-006 -7,560681148 BCL2A1 597 NM_004049.2 1,78E-005 -7,527741084 GPR55 9290 NM_005683.3 8,36E-005 -7,476175621 ARNTL2 56938 NM_020183.3 9,09E-006 -7,464130822 EML4 27436 NM_019063.2 9,11E-006 -7,455394769 FSCN1 6624 NM_003088.2 4,82E-005 -7,434424042 CSF1 1435 NM_000757.3 7,12E-006 -7,421812952 LY75 4065 NM_002349.2 5,42E-006 -7,396251517 VIM 7431 NM_003380.2 3,18E-005 -7,368164191 IRAK1 3654 NM_001569.3 8,59E-006
    [Show full text]
  • STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B Cell Lymphoma
    STAT3 Targets Suggest Mechanisms of Aggressive Tumorigenesis in Diffuse Large B Cell Lymphoma Jennifer Hardee*,§, Zhengqing Ouyang*,1,2,3, Yuping Zhang*,4 , Anshul Kundaje*,†, Philippe Lacroute*, Michael Snyder*,5 *Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305; §Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520; and †Department of Computer Science, Stanford University School of Engineering, Stanford, CA 94305 1The Jackson Laboratory for Genomic Medicine, Farmington, CT 06030 2Department of Biomedical Engineering, University of Connecticut, Storrs, CT 06269 3Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT 06030 4Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT 06520 5Corresponding author: Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305. Email: [email protected] DOI: 10.1534/g3.113.007674 Figure S1 STAT3 immunoblotting and immunoprecipitation with sc-482. Western blot and IPs show a band consistent with expected size (88 kDa) of STAT3. (A) Western blot using antibody sc-482 versus nuclear lysates. Lanes contain (from left to right) lysate from K562 cells, GM12878 cells, HeLa S3 cells, and HepG2 cells. (B) IP of STAT3 using sc-482 in HeLa S3 cells. Lane 1: input nuclear lysate; lane 2: unbound material from IP with sc-482; lane 3: material IP’d with sc-482; lane 4: material IP’d using control rabbit IgG. Arrow indicates the band of interest. (C) IP of STAT3 using sc-482 in K562 cells. Lane 1: input nuclear lysate; lane 2: material IP’d using control rabbit IgG; lane 3: material IP’d with sc-482.
    [Show full text]
  • Supplementary Figure S1 A
    Supplementary Figure S1 A B C 1 4 1 3 1 2 1 2 1 0 1 1 (Normalized signal values)] 2 (Normalized signal values) (Normalized 8 2 10 Log 6 AFFX-BioC AFFX-BioB AFFX-BioDn AFFX-CreX hDFs [Log 6 8 10 12 14 hOFs [Log2 (Normalized signal values)] Supplementary Figure S2 GLYCOLYSIS PENTOSE-PHOSPHATE PATHWAY Glucose Purine/pyrimidine Glucose-6-phosphate metabolism AMINO ACID Fluctose-6-phosphate AMPK METABOLISM TIGAR PFKFB2 methylgloxal GloI Ser, Gly, Thr Glyceraldehyde-3-phosphate ALDH Lactate PYRUVATE LDH METABOLISM acetic acid Ethanol Pyruvate GLYCOSPHINGOLIPID NADH BIOSYNTHESIS Ala, Cys DLD PDH PDK3 DLAT Fatty acid Lys, Trp, Leu, Acetyl CoA ACAT2 Ile, Tyr, Phe β-OXIDATION ACACA Citrate Asp, Asn Citrate Acetyl CoA Oxaloacetate Isocitrate MDH1 IDH1 Glu, Gln, His, ME2 TCA Pro, Arg 2-Oxoglutarate MDH1 CYCLE Pyruvate Malate ME2 GLUTAMINOLYSIS FH Succinyl-CoA Fumalate SUCLA2 Tyr, Phe Var, Ile, Met Supplementary Figure S3 Entrez Gene Symbol Gene Name hODs hDFs hOF-iPSCs GeneID 644 BLVRA biliverdin reductase A 223.9 259.3 253.0 3162 HMOX1 heme oxygenase 1 1474.2 2698.0 452.3 9365 KL klotho 54.1 44.8 36.5 nicotinamide 10135 NAMPT 827.7 626.2 2999.8 phosphoribosyltransferase nuclear factor (erythroid- 4780 NFE2L2 2134.5 1331.7 1006.2 derived 2) related factor 2 peroxisome proliferator- 5467 PPARD 1534.6 1352.9 330.8 activated receptor delta peroxisome proliferator- 5468 PPARG 524.4 100.8 63.0 activated receptor gamma 5621 PRNP prion protein 4059.0 3134.1 1065.5 5925 RB1 retinoblastoma 1 882.9 805.8 739.3 23411 SIRT1 sirtuin 1 231.5 216.8 1676.0 7157 TP53
    [Show full text]
  • Tomatologia Det Man Kann Man United
    TOMATOLOGIAUS009777332B2 DET MAN KANN MAN UNITED (12 ) United States Patent ( 10 ) Patent No. : US 9 , 777 ,332 B2 Campana et al. ( 45 ) Date of Patent : Oct. 3 , 2017 ( 54 ) METHODS AND COMPOSITIONS FOR ( 56 ) References Cited IDENTIFYING MINIMAL RESIDUAL DISEASE IN ACUTE LYMPHOBLASTIC U . S . PATENT DOCUMENTS LEUKEMIA 2006 /0240434 Al 10 /2006 Gabert et al. 2007 / 0020670 A11 / 2007 Loken et al. @( 75 ) Inventors : Dario Campana, Kent Vale (SG ) ; 2012 /0202202 A18 /2012 Wang et al . Elaine Coustan - Smith , Kent Vale (SG ) FOREIGN PATENT DOCUMENTS @( 73 ) Assignee : St. Jude Children ' s Research BR WO 2010140885 A1 * 12 /2010 .. .. GOIN 33/ 5094 Hospital, Memphis , TN (US ) EP 2 259 065 AL 8 / 2010 WO WO 2007 /008759 A2 1 / 2007 ( * ) Notice : Subject to any disclaimer , the term of this WO WO 2010140885 A1 * 12 / 2010 patent is extended or adjusted under 35 U . S . C . 154 (b ) by 233 days . OTHER PUBLICATIONS Campana et al. , Immunophenotyping of Leukemia , Journal of (21 ) Appl. No. : 14 /005 ,921 Immunological Methods, 2000 , 243 , 59 - 74 . * Campana , Minimal Residual Disease in Acute Lymphoblastic Leu (22 ) PCT Filed : Mar . 14 , 2012 kemia , Hematology , 2010 , 7 - 12 . * US Patent and Trademark Office (USPTO ) , Examples , Nature Based Products , Interim Guidance , 2014 , 1 - 17 . * ( 86 ) PCT No .: PCT/ US2012 /028993 Opinion of the United States Court of Appeals for the Federal Circuit, Genetic Technologies Limited v . Merial LLC , 2016 , 1 - 20 . * $ 371 ( c )( 1 ) , Opinion of the United States Court of Appeals for the Federal ( 2 ) , ( 4 ) Date : Oct. 2 , 2013 Circuit, Ariosa Diagnostics , Inc. v . Sequenom , Inc.
    [Show full text]